Jubilant Generics Receives Tentative USFDA Approval for Pantoprazole Suspension
Jubilant Pharmova Limited has received tentative approval from the United States Food and Drug Administration (USFDA) concerning a product manufactured by its subsidiary, Jubilant Generics Limited. The facility involved is the Solid Dosage Manufacturing Facility located in Roorkee.The approval relates to Pantoprazole Sodium Delayed Release Oral Suspension, 40 mg per packet, which was granted on June 25, 2026, at 11:47 am.
This tentative USFDA approval for the specified oral suspension is conditional upon the expiry of the patent covering the Reference Listed Drug (RLD). The patent is currently expected to expire in December 2026. Final approval from the USFDA is anticipated following this patent expiry.
JUBLPHARMA Stock Price Movement
On Thursday, Jubilant Pharmova Limited's stock shed 0.9%, settling at ₹964.4 after falling by ₹8.80 from its previous close. The equity traded a volume of 88,674 shares during the session.Disclaimer: Due care and diligence have been taken in compiling and presenting news and market-related content. However, errors or omissions may arise despite such efforts.
The information provided is for general informational purposes only and does not constitute investment advice, a recommendation, or an offer to buy or sell any securities. Readers are advised to rely on their own assessment and judgment and consult appropriate financial advisers, if required, before taking any investment-related decisions.
Any views, opinions, or statements expressed, where applicable, are those of the respective analysts or experts and do not reflect the views of this website. The website has no association with such viewpoints and does not assume any responsibility for them.